mebendazole has been researched along with Benign Neoplasms in 5 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Flubendazole's potential use in clinical oncology will require further understanding of its mechanistic roles, range of inhibition of cancer types, capacity for adjunctive therapy and possible reformulation for enhanced solubility, bioavailability and potency." | 2.72 | Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent. ( Khachigian, LM, 2021) |
| "There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the quality of life of patients and complicated drug development processes that are costly and time consuming." | 2.53 | Revisiting Non-Cancer Drugs for Cancer Therapy. ( Liu, Y; Lv, J; Sup Shim, J; Wu, C; Yang, EJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Khachigian, LM | 1 |
| Chen, C | 1 |
| Ding, Y | 1 |
| Liu, H | 1 |
| Sun, M | 1 |
| Wang, H | 1 |
| Wu, D | 1 |
| Yang, EJ | 1 |
| Wu, C | 1 |
| Liu, Y | 1 |
| Lv, J | 1 |
| Sup Shim, J | 1 |
| Scheuring, UJ | 1 |
| Seitz, HM | 1 |
| Wellmann, A | 1 |
| Hartlapp, JH | 1 |
| Tappe, D | 1 |
| Brehm, K | 1 |
| Spengler, U | 1 |
| Sauerbruch, T | 1 |
| Rockstroh, JK | 1 |
4 reviews available for mebendazole and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent.
Topics: Antinematodal Agents; Cell Proliferation; Drug Repositioning; Ferroptosis; Humans; Mebendazole; Neop | 2021 |
Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2022 |
Revisiting Non-Cancer Drugs for Cancer Therapy.
Topics: Antineoplastic Agents; Disulfiram; Doxycycline; Drug Repositioning; High-Throughput Screening Assays | 2016 |
1 other study available for mebendazole and Benign Neoplasms
| Article | Year |
|---|---|
Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination.
Topics: Albendazole; Anticestodal Agents; Benzimidazoles; Bone Diseases, Infectious; Diagnosis, Differential | 2003 |